Mantle cell lymphoma: evolving management strategies, Blood, vol.125, issue.1, pp.48-55, 2015. ,
Molecular pathogenesis of mantle cell lymphoma, J Clin Invest, vol.122, issue.10, pp.3416-3423, 2012. ,
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, issue.16, pp.3161-3164, 2013. ,
Pharmacological and genomic profiling identifies NF-kB-targeted treatment strategies for mantle cell lymphoma, Nat Med, vol.20, issue.1, pp.87-92, 2014. ,
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc Natl Acad Sci, vol.110, issue.45, pp.18250-18255, 2013. ,
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies, Semin Cancer Biol, vol.24, pp.71-81, 2014. ,
The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity, Semin Cancer Biol, vol.24, pp.23-32, 2014. ,
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies, Semin Cancer Biol, vol.21, issue.5, pp.308-312, 2011. ,
Egress of CD19(1)CD5(1) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, issue.14, pp.2412-2424, 2013. ,
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013. ,
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02534385
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma, Br J Haematol, vol.170, issue.1, pp.131-134, 2015. ,
Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease, Leuk Lymphoma, vol.56, issue.1, pp.186-193, 2015. ,
Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a, Blood, vol.116, issue.24, pp.5228-5236, 2010. ,
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, pp.4604-4613, 2009. ,
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas, Blood, vol.110, issue.5, pp.1631-1638, 2007. ,
CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines, Anticancer Res, vol.24, issue.2B, pp.691-697, 2004. ,
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of Bcell activating factor and activation of the canonical and non-canonical nuclear factor kB pathways, Haematologica, vol.97, issue.8, pp.1255-1263, 2012. ,
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4, Leukemia, vol.14, issue.2, pp.292-298, 2000. ,
Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures, Blood, vol.96, issue.6, pp.2219-2225, 2000. ,
Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system', Leukemia, vol.10, issue.3, pp.488-493, 1996. ,
TLR9 ligand induces the generation of CD201 plasmablasts and plasma cells from CD271 memory B-cells, Front Immunol, vol.2, p.83, 2011. ,
Generation of memory B cells and plasma cells in vitro, Science, vol.268, issue.5211, pp.720-722, 1995. ,
URL : https://hal.archives-ouvertes.fr/hal-02474293
3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jetsprayed or electrospun micro-fiber scaffolds, Biomed Mater, vol.10, issue.4, p.45019, 2015. ,
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, issue.4, pp.285-288, 2015. ,
Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot, PLoS One, vol.8, issue.7, p.68425, 2013. ,
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells, ACS Chem Biol, vol.9, issue.9, pp.1962-1968, 2014. ,
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL ,
, J Mol Biol, vol.427, pp.1241-1253, 2015.
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, 2010. ,
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells, Blood, vol.120, issue.18, pp.3783-3792, 2012. ,
Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma, Haematologica, vol.96, issue.6, pp.871-880, 2011. ,
Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma, Cancer Res, vol.65, issue.2, pp.587-595, 2005. ,
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma, Blood, vol.111, issue.10, pp.5142-5151, 2008. ,
Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23, Mod Pathol, 1994. ,
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, vol.12, issue.2, pp.115-130, 2007. ,
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01353369
, Br J Haematol
BCL2/BCL-X (L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation, Blood, vol.117, issue.26, pp.7145-7154, 2011. ,
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes, Oncogene, vol.26, issue.13, pp.1910-1919, 2007. ,
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis, J Immunol, vol.171, issue.1, pp.88-95, 2003. ,
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis, Cancer Res, vol.65, issue.1, pp.264-276, 2005. ,
Obinutuzumab in hematologic malignancies: lessons learned to date, Cancer Treat Rev, vol.41, issue.9, pp.784-792, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01962569
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, issue.9, pp.1022-1035, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02490276
Pathogenic role of B-cell receptor signaling and canonical NF-kB activation in mantle cell lymphoma, Blood, vol.128, issue.1, pp.82-92, 2016. ,
T-cell levels are prognostic in mantle cell lymphoma, Clin Cancer Res, vol.20, issue.23, pp.6096-6104, 2014. ,
Characteristics of human primary mantle cell lymphoma engraftment in NSG mice, Br J Haematol, vol.173, issue.1, pp.165-169, 2016. ,
Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia, Blood, vol.120, issue.17, pp.3501-3509, 2012. ,
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia, Blood, vol.113, issue.18, pp.4403-4413, 2009. ,
,
, Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma, LYM-3002 Investigators, vol.372, pp.944-953, 2015.
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors, Haematologica, vol.100, issue.8, pp.302-306, 2015. ,
Differential regulation patterns of the anti-CD20 ,
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity, Blood, vol.115, issue.22, pp.4393-4402, 2010. ,
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study, J Clin Oncol, vol.31, issue.23, pp.2912-2919, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01704593
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial, Lancet Oncol, vol.17, issue.8, pp.1081-1093, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800013
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kd inhibition through PIK3IP1, Cell Cycle, vol.12, issue.12, pp.1892-1900, 2013. ,
, online October, vol.3, pp.2808-2818, 2016.
,
Sophie Maiga, expansion of mantle cell lymphoma Rational targeted therapies to overcome microenvironment-dependent ,
, Information about subscriptions and ASH membership may be found online at: Copyright 2011 by The, Lymphoid Neoplasia Articles on similar topics can be found in the following Blood collections, 20036.
, Blood